Verrica Pharmaceuticals Inc.
VRCA
$6.11
-$0.04-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.58M | 30.83M | 14.70M | 7.18M | 7.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.58M | 30.83M | 14.70M | 7.18M | 7.57M |
| Cost of Revenue | 12.30M | 10.17M | 9.69M | 11.22M | 14.58M |
| Gross Profit | 23.28M | 20.66M | 5.01M | -4.04M | -7.01M |
| SG&A Expenses | 35.22M | 36.98M | 43.66M | 51.33M | 58.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.52M | 47.15M | 53.36M | 62.55M | 73.40M |
| Operating Income | -11.94M | -16.32M | -38.65M | -55.37M | -65.84M |
| Income Before Tax | -17.89M | -26.01M | -48.60M | -65.99M | -76.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.89 | -26.01 | -48.60 | -65.99 | -76.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.89M | -26.01M | -48.60M | -65.99M | -76.58M |
| EBIT | -11.94M | -16.32M | -38.65M | -55.37M | -65.84M |
| EBITDA | -11.45M | -15.76M | -37.95M | -54.53M | -64.88M |
| EPS Basic | -1.61 | -3.44 | -8.30 | -12.01 | -15.36 |
| Normalized Basic EPS | -0.93 | -2.14 | -5.18 | -7.50 | -9.59 |
| EPS Diluted | -1.61 | -3.44 | -8.30 | -12.02 | -15.36 |
| Normalized Diluted EPS | -0.93 | -2.14 | -5.18 | -7.50 | -9.59 |
| Average Basic Shares Outstanding | 42.57M | 35.19M | 30.38M | 25.55M | 20.71M |
| Average Diluted Shares Outstanding | 42.57M | 35.20M | 30.39M | 25.55M | 20.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |